* Cabozantinib met primary endpoint of improving
progression-free survival as compared to Sunitinib
The post BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Cabozantinib met primary endpoint of improving
progression-free survival as compared to Sunitinib
The post BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib appeared first on NASDAQ.